Loading...
NPI 1255468328 · Brooklyn, NY · Clinical Medical Laboratory
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Lenco Diagnostic Laboratories,inc. is a clinical medical laboratory provider located in Brooklyn, New York. This profile covers 272 Medicare and 320 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Organization |
| Organization | Lenco Diagnostic Laboratories,inc. |
| Address | 1857 86th St |
| City | Brooklyn |
| State | NY |
| ZIP | 11214 |
| Taxonomy | Clinical Medical Laboratory |
| NPI Enumerated | February 27, 2007 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicaid | $105.1M |
| Medicare | $9.5M |
Payer mix is heavily skewed toward Medicaid: the provider reports $105.1M in total Medicaid revenue compared with $9.5M in Medicare revenue, indicating Medicaid is the dominant payer by an order of magnitude and likely the primary driver of operational scale and cash flow. This imbalance suggests contracts and utilization patterns will be most visible and material in Medicaid data.
The code mix identifies LENCO DIAGNOSTIC LABORATORIES,INC. as a high-volume outpatient clinical laboratory with broad test coverage: high-volume chemistry and panel work (80061, 80053), endocrine and vitamin testing (82306, 82607, 84443), infectious disease molecular testing (U0003, 87637), and common screening tests (83036, 85025). Medicaid volumes in particular show very large claim counts for molecular and routine tests (for example U0003: 336.3K claims; 82306: 326.5K claims), consistent with a high-throughput reference lab model that services both diagnostic and population-level testing needs.
Revenue concentration differs by payer: the top three Medicare codes account for 27.9% of the provider’s Medicare revenue, while the top three Medicaid codes account for 47.8% of its Medicaid revenue. This indicates Medicaid revenue is more concentrated in a few high-volume services (notably U0003 and 82306 on the Medicaid side), increasing the impact of those specific codes on overall Medicaid performance.
Competitive standing on Medicare shows nationally extreme volumes for many routine lab codes: 82306 ranks #37 of 12453 providers nationally (100th percentile; extreme outlier), 82607 ranks #32 of 11159 (100th percentile; extreme outlier), and several other routine assays are at or near the 100th percentile. These rankings characterize the provider as an outsized national biller for multiple common laboratory assays on the Medicare side, not a modest or niche contributor.
Competitive standing in New York Medicaid demonstrates a dominant in‑state position for several services: U0003 generates $25.6M (33.1% of Medicaid revenue) and ranks #7 of 336 in-state (98th percentile; extreme outlier), 82306 generates $6.2M and ranks #2 of 384 (100th percentile; extreme outlier), and 86769 ranks #2 in-state as well. Collectively these high ranks and large dollar volumes indicate the provider is a major statewide player for SARS‑CoV‑2 molecular and serologic testing and high-volume routine assays.
Operational footprint signals built collection and logistics capacity: claims for travel/prorated specimen collection (P9604: 9.7K claims, $212.5K revenue) and venipuncture (36415: 14.4K claims, $115.3K revenue) show the provider bills for specimen collection services in addition to laboratory analyses. High claim counts across both collection and testing codes imply a vertically integrated or coordinated specimen‑handling operation that supports outreach or home/nursing‑home collection workflows.
Service mix includes both high-throughput molecular diagnostics and high-volume preventive/management testing, which has payer implications for utilization management and contracting. Medicaid shows large revenue for mass SARS‑CoV‑2 testing codes (U0003: $25.6M, 33.1% of Medicaid revenue; U0005: $4.9M) alongside routine chronic‑disease monitoring tests (83036, 80061), suggesting payers should evaluate both transactional pricing for molecular panels and capitation/volume terms for routine chronic disease monitoring.
Tenure and market stability: the NPI was enumerated on 2007-02-27 (~19 years ago), indicating this is an established laboratory operation with a long billing history. Combined with the concentrated Medicaid revenue base and repeated high percentile rankings, the provider appears to be a long‑standing, high‑volume regional lab whose Medicaid activity will be the primary determinant of contractual leverage and utilization impact.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
272 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 82306 | The lab analyst measures the vitamin D level, typically on a serum specimen. This analyte, commonly known as vitamin D, is not really a vitamin, but is an important steroid hormone that is produced… | 27,590 | $30 | $800.2K |
| 84443 | The lab analyst performs a test to measure the amount of thyroid–stimulating hormone (TSH), a hormone produced in the pituitary gland that helps regulate thyroid function. The typical specimen is the… | 35,980 | $20 | $575.7K |
| 80061 | The lab analyst performs a lipid panel test in which he measures the blood level of cholesterol and fats called triglycerides in the blood. | 40,070 | $10 | $520.9K |
| 87637 | The lab analyst performs the technical steps to detect and differentiate severe acute respiratory syndrome coronavirus 2 (SARS–CoV–2), influenza A, influenza B, and respiratory syncytial virus (RSV)… | 3,460 | $140 | $484.1K |
| 80053 | The lab analyst performs a comprehensive metabolic panel, or CMP test in which he measures the blood level of 14 chemicals the code descriptor lists for the panel. | 47,330 | $10 | $473.3K |
| 82607 | The lab analyst performs a test to measure the amount of vitamin B12 in a patient specimen, typically in patient blood. | 27,820 | $20 | $417.3K |
| 83036 | Sugar in the bloodstream can get attached to the hemoglobin in red blood cells. Once the sugar is attached, it stays there for the lifetime of the red blood cell (around 120 days or over 3 months).… | 37,870 | $10 | $378.7K |
| 85025 | A complete blood count (better known as a CBC) is a blood test request by a doctor that provides detailed information about various types of cells in a patient's blood. Usually a pathologist or a… | 46,600 | $10 | $372.8K |
| 83880 | The lab analyst measures the amount of natriuretic peptide, a hormone made by heart muscle cells, in the patient specimen. Blood levels of the hormone increase in patients with congestive heart… | 8,550 | $40 | $324.8K |
| 82746 | The lab analyst measures the folic acid level in serum to determine if there is a deficiency. Folic acid deficiency is attributed to many conditions such as malabsorption, Crohn’s disease, celiac… | 19,610 | $10 | $274.5K |
Showing 1–10 of 272
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 272 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
272 rows
| CPT/HCPCS Code | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|
| P9604 | 2 | 10 | 1,880 | $20 | $306.6K |
| 87798 | 36 | 40 | 740 | $30 | $218.3K |
| 88120 | 31 | 30 | 90 | $450 | $133.6K |
| G0483 | 12 | 20 | 270 | $240 | $82.4K |
| 87801 | 10 | 20 | 60 | $70 | $75.1K |
| 81539 | 2 | 10 | 80 | $740 | $61.8K |
| 88305 | 279 | 980 | 370 | $50 | $58.5K |
| 87636 | 6 | 180 | 20 | $140 | $54.9K |
| G0481 | 20 | 30 | 150 | $150 | $50.1K |
| 87481 | 14 | 40 | 80 | $30 | $45.5K |
Showing 1–10 of 272
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
320 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 336,310 | $80 | $25.6M |
| 82306 | The lab analyst measures the vitamin D level, typically on a serum specimen. This analyte, commonly known as vitamin D, is not really a vitamin, but is an important steroid hormone that is produced… | 326,530 | $20 | $6.2M |
| 86769 | The lab analyst performs a multiple–step immunoassay to evaluate the patient’s serum for antibodies to severe acute respiratory syndrome coronavirus 2 (SARS–CoV–2), which causes coronavirus disease… | 151,220 | $30 | $5.1M |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc,… | 231,880 | $20 | $4.9M |
| 80050 | The lab analyst performs testing for the specific group of clinical laboratory procedures in the general health panel. Payers typically consider 80050 to apply only when the clinician orders the… | 193,640 | $20 | $3.9M |
| 87637 | The lab analyst performs the technical steps to detect and differentiate severe acute respiratory syndrome coronavirus 2 (SARS–CoV–2), influenza A, influenza B, and respiratory syncytial virus (RSV)… | 30,670 | $100 | $3.1M |
| 83036 | Sugar in the bloodstream can get attached to the hemoglobin in red blood cells. Once the sugar is attached, it stays there for the lifetime of the red blood cell (around 120 days or over 3 months).… | 459,380 | $10 | $2.8M |
| 86481 | The lab analyst performs a test to evaluate an antigen response to certain tuberculosis (TB) antibodies by enumerating T cells that produce gamma interferon. | 72,450 | $40 | $2.5M |
| 87491 | The lab analyst performs a test for Chlamydia trachomatis using amplified nucleic acid probe technique. | 165,700 | $20 | $2.5M |
| 80053 | The lab analyst performs a comprehensive metabolic panel, or CMP test in which he measures the blood level of 14 chemicals the code descriptor lists for the panel. | 379,670 | $10 | $2.3M |
Showing 1–10 of 320
How this provider's Medicaid billing volume and revenue compare to other New York providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. New York median
320 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 7 | 340 | 1,090 | $70 | $1.4M |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 5 | 40 | 440 | $90 | $511.9K |
| 87633 | The lab analyst performs a test to identify a respiratory virus using amplified nucleic acid probe technique. He may also use a multiplex reverse transcription technique. The provider does this for… | 17 | 140 | 360 | $130 | $492.1K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc,… | 7 | 300 | 1,710 | $20 | $458.6K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 12 | 110 | 690 | $50 | $442K |
| 80307 | The lab analyst performs presumptive drug test(s) via instrumented chemistry analyzers to screen for any number of drug classes on a single date. | 8 | 290 | 1,900 | $30 | $390.6K |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 5 | 30 | 550 | $100 | $359.8K |
| 81220 | The lab analyst performs the technical lab test to detect the presence of changes in the gene for cystic fibrosis transmembrane conductance regulator, also known as CFTR. The test evaluates the CFTR… | 41 | 60 | 230 | $370 | $340.9K |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 17 | 20 | 240 | $70 | $302K |
| 86481 | The lab analyst performs a test to evaluate an antigen response to certain tuberculosis (TB) antibodies by enumerating T cells that produce gamma interferon. | 2 | 30 | 1,350 | $40 | $300.8K |
Showing 1–10 of 320
Other providers in the same ZIP code as Lenco Diagnostic Laboratories,inc., ranked by combined Medicare and Medicaid revenue.
| Provider | State | Taxonomy | Medicare Revenue | Medicaid Revenue |
|---|---|---|---|---|
| 1st Choice Home Care Services, Inc | NY | Home Health Agency | $0 | $172.1M |
| Signature Care, LLC | NY | Home Health Agency | $0 | $114.2M |
| Signature Care Cdpap, LLC | NY | Home Health Agency | $0 | $69.9M |
| Prolife Home Care, Inc. | NY | Home Health Agency | $0 | $60.1M |
| Gsny Home Care Services, Inc. | NY | Home Health Agency | $0 | $35.3M |
| Happy Family Social Adult Center Inc | NY | Adult Day Care Clinic/Center | $0 | $30.9M |
| 1st Choice Home Care Services, Inc. (cdpap) | NY | Home Health Agency | $0 | $28.5M |
| Asian Senior Care Center Inc | NY | Adult Day Care Clinic/Center | $0 | $19.4M |
| Family Social Adult Day Care | NY | Adult Day Care Clinic/Center | $0 | $19.1M |
| Andrey Kesler | NY | Optometrist | $44.9K | $6.6M |
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.